Phase II/III of Cediranib and Olaparib or Standard Chemotherapy

To assess the efficacy and identify (in)active arm(s) of the combination of cediranib (cediranib maleate) and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by progression-free survival (PFS) in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer.

August 09, 2017

  • Clinical Trial Information

    Trial Contact: Quintiliani, Jennifer

    Trial Phone: 321.843.2026

  • Age Group: Adult

    Phase: Drug: Phase II

    Principal Investigator: Veronica L Schimp, DO

    Sub Investigators:

    IRB No:

    Secondary Protocol No: NRG GY005

    Applicable Disease Sites: Ovarian, Fallopian Tube or Primary Peritoneal Cancer